Multiple electrode aggregometry and P2Y12 antagonists

Thrombosis and Haemostasis

Volumn 99, Issue 6, 2008, Pages 1127-1129

  Johnson, Andrew ^b   Dovlatova, Natalia ^b   Heptinstall, Stan ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; AR C 69931; CANGRELOR; CITRIC ACID; CLOPIDOGREL; CLOPIDOGREL METABOLITE; HIRUDIN; PRASUGREL; PRASUGREL METABOLITE; PROSTAGLANDIN E1; PURINE ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST;

ANALYTIC METHOD; BLOOD CLOTTING; DEVICE; HUMAN; LETTER; MULTIPLE ELECTRODE AGGREGOMETRY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES; EQUIPMENT DESIGN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; THIOPHENES; TICLOPIDINE;

EID: 44949262856     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-01-0054     Document Type: Letter

References (16)

1. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thomb Haemost 2008; 99: 121-126.
2. Tóth O, Calatzis A, Penz S et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
3. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer - comparison with two flow cytometric methods. Thromb Res 2007; 121: 249-258.
4. Seyfert UT, Haubelt H, Vogt A, et al. Variables influencing Multiplate™ whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206.
5. Mengistu AM, Wolf MW, Boldt J et al. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. Cardiothorac Vasc Anesth 2008; 22: 40-46.
6. http://www.multiplate.net. Accessed on January 26, 2008.
7. Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP et al. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100™). Platelets 2007; 18: 491-46.
8. Perneby C, Wallén NH, Hofman-Bang C, et al. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. Thromb Haemost 2007; 98: 1316-1322.
9. Neubauer H, Lask S, Engelhardt A, et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
10. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
11. 12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004; 35: 39-46.
12. http://www.themedicinescompany.com/products_cangrelor.shtml
13. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
14. Parikh SA, Beckman JA. Contemporary use of clopidogrel in patients with coronary artery disease. Curr Cardiol Rep 2007; 9: 257-263.
15. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008 Mar 27 [E-pub ahead of print].
16. Frelinger III AL, Jakubowski JA, Li Y, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192-200.